key: cord-1011345-ou7si2ib
authors: Brandão, Thaís Bianca; Gueiros, Luiz Alcino; Melo, Thayanara Silva; Prado-Ribeiro, Ana Carolina; Nesrallah, Ana Cristina Froelich Alo; do Prado, Gladys Villas Boas; Santos-Silva, Alan Roger; Migliorati, Cesar Augusto
title: Oral lesions in SARS-COV-2 infected patients: could the oral cavity be a target organ?
date: 2020-08-18
journal: Oral Surg Oral Med Oral Pathol Oral Radiol
DOI: 10.1016/j.oooo.2020.07.014
sha: 9d9df2989d2dc21ff83616fb40c4796979959738
doc_id: 1011345
cord_uid: ou7si2ib

Several viruses transmitted through saliva, such as herpes simplex virus, cytomegalovirus and Zika virus are capable of infecting and replicating in the oral mucosa leading to painful oral ulcers. Few studies have described COVID-19 oral manifestations. There is growing evidence that angiotensin-converting enzyme 2 (ACE2), the main host cell receptor of SARS-CoV-2, is highly expressed on the epithelial cells of the tongue and salivary glands, which may explain the development of dysgeusia in COVID-19 patients. Hence, it is important to understand if SARS-CoV-2 can infect and replicate in oral keratinocytes and fibroblasts, causing oral ulcerations and superficial necrosis. Herein we report a series of eight cases of COVID-19 infected patients with oral necrotic ulcers and aphthous-like ulcerations affecting tongue, lips, palate and oropharynx that developed early in the course of disease following the development of dysgeusia. A short review of the literature regarding the important role of ACE2 in SARS-CoV-2 cellular entry is also provided bringing new insights to oral keratinocytes and minor salivary glands as potential targets.

The coronavirus disease 2019 (COVID-19) had a massive impact worldwide due to mode of infection spread, the severe acute respiratory syndrome, and global death toll. Since the identification of this new airborne infectious microorganism (SARS-CoV-2) in Wuhan, China, millions of cases were diagnosed worldwide, with mortality rates varying from 3% to 12% 1 .

In addition to fever, fatigue, dry cough, myalgias, sore throat, breathing difficulties, and respiratory complications that often deteriorate to severe acute respiratory syndrome, patients infected by SARS-CoV-2 may develop a myriad of other local and systemic complications, such as acute cardiac damage, acute renal failure, gastrointestinal complications, dysgeusia, anosmia, and neurological symptoms, including Guillain Barre syndrome [2] [3] [4] . SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor (ACE2), which is detected in the cell membrane of numerous human organs and tissues, including lungs, kidneys, liver, epithelial cells of the tongue and salivary glands, upper respiratory tract, nervous system, and skeletal muscle, among others [5] [6] [7] [8] .

Although SARS-CoV-2 can be detected in the saliva and oropharyngeal secretions [9] [10] [11] [12] , the infection routes of the disease remain elusive and little is known about its transmission routes through the oral mucosa. Thus, more clinical evidence and research are needed in order to confirm the ability of SARS-CoV-2 to infect oral tissues and its pathogenic mechanisms in the oral and oropharyngeal mucosa. This case series shows two patterns of oral ulcerationsaphthous-like and superficial necrosis affecting multiple oral sites of patients diagnosed with COVID-19. These lesions developed in oral sites known to express ACE2 receptors as recently described in the tongue epithelium and the salivary glands tissue 6, 7 , following the complaint of dysgeusia.

An 81-year-old man with cough and progressive chest tightness for 10 days was admitted in the Emergency Department of the Hospital Sírio-Libanês, São Paulo, Brazil, in March 26, 2020. The patient had a history of well-controlled hypertension and chronic obstructive pulmonary disease.

Fifteen days earlier, he had contact with a family member who had travelled to Israel on March 11 and was recently diagnosed with SARS-CoV-2 pneumonia. Dysgeusia appeared on March 16. Five days later the patient developed chills and fever, with a maximum body temperature of 37.7•C. On

March 25, the patient developed a dry cough and mild dyspnea. The physical examination revealed normal body temperature (36•C), blood pressure of 108/67 mm/Hg, heart rate 83 beats/minute, respiratory rate 25/minute, and oxygen saturation of 97%. He was conscious and had no dyspnea, at the time of hospitalization. Biochemical examination showed that leukocytes, and the neutrophils/lymphocytes ratio were all in the normal range (420/mm 3 ), the C-reactive protein level was 23.4 mg/L, and glucose 97 mg/L. The diagnosis of COVID-19 infection was based on the realtime reverse-transcriptase-polymerase chain reaction (rRT-PCR) amplification of the viral DNA from a pharyngeal sample. Computed tomography scan (CT) revealed multiple "ground glass" images in both lungs.

The patient was placed in a special isolation ward and was treated with azithromycin and ceftriaxone for 7 days. Head and neck examination did not identify asymmetries, swellings or enlarged cervical lymph nodes. Oral examination revealed multiple shallow aphthous-like ulcers with variable size and irregular margins covered with mucopurulent membrane suggesting superficial necrosis in the upper and lower lip mucosa as well as the anterior dorsal tongue ( Figures 1A and 1B) .

The lesions were painful on palpation and believed to have developed in the last few days, synchronously to hospital admission. Herpes simplex virus (HSV-1) was detected by a PCR of saliva sample and the patient was immediately started on intravenous acyclovir 250 mg/m 2 three times a day for 10 days. There was no clinical improvement. As an adjuvant measure to manage the pain associated with the oral ulcers, a trained dentist administered daily photobiomodulation therapy (PBMT) for 10 consecutive days. The PBMT device (Twin Flex, MMOptics, São Carlos, Brazil) was positioned perpendicular to the oral ulcers surface, 10 s per site operating at 660 nm wavelength, 40 mW average power, 0.04 cm 2 beam area, 1 W/cm 2 irradiance, 0.4 J energy and 10 J/cm 2 fluence. This is our protocol of PBMT used for patients with oral mucositis associated with cancer therapy. The patient reported symptoms relief after 2 days of PBMT and the oral lesions completely resolved after 11 days of PBMT. After 16 days in the intensive care unit and 14 additional days in a critical care unit, his clinical course and respiratory status showed improvement. He was discharged and is currently recovering well at home.

A 71-year-old female was admitted to the Emergency Department of Hospital Sírio-Libanês, São Paulo, Brazil, on April 08, 2020, with symptoms of severe acute respiratory syndrome. Four days prior to hospitalization, the patient developed cough, dysgeusia, fever and mild dyspnea. Past medical history was significant for hypertension, diabetes, obesity and renal failure. In addition, she reported bariatric surgery and fibromyalgia. On physical examination the body temperature was 38.5•C, with blood pressure of 130/66 mm/Hg, heart rate 92 beats/minute, respiratory rate 20/minute, and oxygen saturation of 90% on room air. The laboratory exams confirmed serum glucose of 156 mg/dL, creatinine 0.69 mg/dL, white blood cell count 6,930 cells per microliter (neutrophils = 83.2%; lymphocytes = 15%), c-reactive protein 16.5 mg/dL, and hemoglobin 10.7 g/dL. Lung CT demonstrated diffuse "ground-glass" hyperdense images in both lungs. rRT-PCR for SARS-CoV-2 was positive and the patient was treated with azithromycin for 20 days and ceftriaxone for 3 days.

Head and neck examination was negative for lymphadenopathy. The intraoral examination identified small hemorrhagic ulcerations affecting the upper and lower lips as well as focal areas of shallow necrosis on the anterior dorsal tongue ( Figure 2 ). These lesions developed simultaneously to hospital admission. Herpes simplex virus (HSV-1) was detected by a PCR of saliva sample. The patient was immediately started on intravenous acyclovir 250 mg/m 2 three times a day for 7 days and showed no clinical improvement. Due to the severe pain associated with the ulcers, the patient received daily treatments of PBMT following the same protocol described above. The intraoral lesions presented signs of clinical regression after 10 days of light therapy, however, lip ulcerations did not respond after 15 days of PBMT. Because of respiratory symptom progression, on April 10, 2020 the patient was placed on mechanical ventilator support aiming to avoid acute respiratory failure and is still in critical condition under intensive care.

An 83-year-old female patient was admitted to the Emergency Department of Hospital Sírio-Libanês, São Paulo, Brazil, in May 20, 2020 due to abdominal distension and mild dyspnea. Her past medical history was significant for obesity, Parkinson's disease, hypertension, pancreatitis, and chronic pulmonary obstructive disease. On physical examination her body temperature was 37.5•C, with blood pressure of 189/71 mm/Hg, heart rate 82 beats/minute, respiratory rate 17/minute, and oxygen saturation of 98% on room air. Her laboratory results showed serum glucose 134 mg/dL, creatinine 0.85 mg/dL, white blood cell count 10,620 cells per microliter (neutrophils = 86%; lymphocytes = 7.3%); c-reactive protein 3.45 mg/dL, and hemoglobin 12 g/dL. Lung CT showed discreet hyperdense images in both lungs. rRT-PCR for SARS-CoV-2 was positive and the patient was placed in an isolation ward and treated with piperacillin/tazobactam and ceftriaxone.

Head and neck examination was negative. The intraoral examination identified a 1.5 x 1.5 cm ulcer on the right lateral border of the tongue as well as a discreet area in the anterior hard palate affected by a petechia and a shallow necrotic area ( Figures 3A and 3B ). Both lesions were painful and developed simultaneously to hospital admission. Herpes simplex virus (HSV-1) PCR of saliva was negative. The patient started receiving PBMT following the standard hospital protocol. Complete pain control was obtained after 5 days of light therapy. Because of the mild respiratory symptoms, the patient was placed in a critical care unit and is currently showing improvement after 10 days of hospitalization.

A 72-year-old male patient checked into the emergency room (ER) complaining of fever and dyspnea lasting for several days. He was admitted to the Emergency Department of Hospital Sírio-Libanês, São Paulo, Brazil, on April 29, 2020 with a past medical history of diabetes and hypertension. On physical examination his body temperature was 36.0•C, with blood pressure of 150/91 mm/Hg, heart rate 75 beats/minute, respiratory rate 23/minute, and oxygen saturation of 91% on room air. The laboratory results were serum glucose 170 mg/dL, creatinine 0.93 mg/dL, white blood cell count 8,450 cells per microliter (neutrophils = 83.1%; lymphocytes = 9.9%), c-reactive protein 19.39 mg/dL, and hemoglobin 15.3 g/dL. Lung CT demonstrated diffuse hyperdense images in both lungs affecting approximately 50% of both lungs. rRT-PCR for SARS-CoV-2 from a nasopharyngeal swab was positive. The patient was treated with piperacillin/tazobactam, azithromycin, and Rocefin.

Regional head and neck examination did not reveal relevant changes. The intraoral examination identified small hemorrhagic ulcerations affecting the upper and lower lip as well as one painful necrotic ulceration on the right lower lip mucosa (Figures 4A and 4B ). These lesions were detected a few days following hospital admission. Herpes simplex virus (HSV-1) was detected by PCR from a saliva sample and the patient started on intravenous acyclovir 250 mg/m2 three times a day for 7 days without clinical improvement. Oral necrotic ulcerations were also managed by PBMT.

The intraoral lesions presented signs of pain and clinical regression after 7 days of light therapy.

Respiratory symptoms did not improve. The patient is still in critical condition under intensive care following 30 days of hospitalization.

A 32-year-old female patient checked into the ER complaining of fever, cough, and headache lasting for five days. She was otherwise healthy, and medical history was non-contributory. The physical examination failed to show cardiovascular, pulmonary, abdominal, or neurological alterations. Her body temperature was 38.5°C, and oxyhemoglobin saturation was 98%. Blood and urine tests were normal, with C-reactive protein and white blood cell count within the normal range.

The nasopharyngeal swab for amplification of the SARS-CoV-2 RNA was collected and showed to be positive. She was diagnosed with mild COVID-19, discharged from the hospital and sent home for 14 days of quarantine, and dipyrone 1 g 4x/day to control the fever. Eight days after the onset of the symptomatic phase, she progressed with anosmia and, on the 10th day, she observed multiple ulcers on the apex and lateral borders of the tongue. On teleconsultation with an oral medicine specialist, she denied to a previous history of recurrent oral ulcers, oral inflammatory disease, or allergy. Clinical pictures were provided by the patient, revealing the lesions to be shallow and circular with a whitish center, surrounded by an erythematous halo and ranging from 3 to 4 mm (Figures 5A and 5B) . She recovered well from COVID-19 after 14 days. Oral lesions had clinical regression approximately after 8 days and no additional lesions were noted thereafter.

A 35-year-old male patient went to the emergency room with complaints of fever, cough, sore throat, and general malaise for the last three days. He was otherwise healthy and did not report the chronic use of any medication. Upon physical examination at the ER, no significant changes were observed, and laboratory tests were within the normal range. Based on clinical presentation, a nasopharyngeal swab test for amplification of the SARS-CoV-2 RNA was collected and turned positive, confirming mild COVID-19. After hospital discharge, the patient was instructed to comply with the quarantine protocol at home. Six days after the onset of symptoms, he still had persistent fever and progressed primarily with hyposmia, ageusia and then with and oral ulcer in the tonsillar pillar, causing mild odynophagia. On teleconsultation, he reported it was the first onset of oral ulcers, denying past history of recurring aphthous stomatitis or any other ulcerative disease of the mouth. The lesion was shallow and had a circular pattern, covered by a fibrinopurulent membrane and surrounded by an erythematous halo, measuring 0.5 cm ( Figure 5C ). He presented full medical recovery at the end of the quarantine, with complete resolution of the oral lesion as well.

A 29-year-old male patient went to the emergency room complaining of fever, cough, headache, dyspnea on exertion and general malaise lasting for 3 days. His medical history was unremarkable with no reported associated diseases or medication use. No organ involvement was noted on physical examination, and oxyhemoglobin saturation was 96% in ambient air. His body temperature was 38°C and laboratory tests were within the normal range. The nasopharyngeal swab test for amplification of the SARS-CoV-2 RNA was positive. He started Ipratropium bromide and fenoterol hydrochloride and was discharged from the hospital to comply with the quarantine protocol at home. On the sixth day of the symptomatic phase he developed anosmia and ageusia. Two days later he observed a painful ulcer in the ventral portion of the tongue. On teleconsultation, the provider noted a shallow ulcer, measuring 1 cm in diameter, with a whitish pseudomembrane surrounded by an erythematous halo ( Figure 5D ). He denied previous history of recurrent oral ulcers and refused any drug treatment. The lesion lasted 6 days and he recovered uneventfully.

A 28-year-old male patient presented to the emergency department with cough, fever (38.5°C), headache, myalgia and chills for 4 days. Physical examination was unremarkable, the oxyhemoglobin saturation was 99% in ambient air and laboratory tests were within normal limits. He denied any relevant diseases or chronic use of any medication. The nasopharyngeal swab tested for amplification of the SARS-CoV-2 RNA was positive and he was oriented to maintain the quarantine protocol at home. After two days he developed anosmia and ageusia and on the eighth day he observed oral aphthous-like ulcers in the upper and lower labial mucosa. Another ulcer was observed on the right lateral border of the tongue after two days (Figures 5E and 5F ). The patient initiated 0.12% non-alcoholic chlorexidine mouthwash and recovered after 4 days. No complications of COVID-19 were noted, and he presented complete healing of the oral lesions 9 days after the onset.

This case series reports several SARS-Cov-2 infected patients who developed oral manifestations during the infectious period of their disease. Of importance, the oral manifestations appeared concomitant with the loss of taste and smell. The oral lesions were more severe and widespread in elderly patients with more severe COVID-19 infection. The observed lesions presented two well-defined and distinct patterns, one resembling aphthous-like ulcers in young patients with mild cases of COVID-19 and another with more widespread patterns resembling HSV-1 necrotic ulcers in the more severe and immunosuppressed older individuals (Table 1) .

The large variety of signs and symptoms that have been associated with COVID-19 disease include dysgeusia and anosmia even in the absence of respiratory symptoms 13 . The recently published tropism of SARS-CoV-2 to the tongue and salivary gland epithelium 6,7 is of importance, suggesting that the oral mucous membrane may be a target organ of the virus 14 . Although we did not sample the oral lesions for COVID-19 presence, we observed that the evolution of the oral lesions and the healing process occurred in parallel with the resolution of the COVID-19 infection. This leads us to speculate that the development of oral manifestations in these patients may be directly associated with the COVID-19 infection. Whether they are caused directly by the virus or it is an associated manifestation resulting from the severe compromised of the patient remains to be determined.

Nevertheless, considering that the distribution of ACE2 receptors may determine the route of SARS-CoV-2 infection, the recently described presence of the ACE2 receptors on the tongue and salivary glands suggest that the epithelial cells of the tongue and salivary glands may be involved in COVID-19 infection and its dysfunction. This could lead to the development of dysgeusia and oral mucosa ulcerations and necrosis 14 . Thus, mutual interaction between SARS-CoV-2 and ACE2 might disrupt the function of oral keratinocytes and the epithelial lining of salivary glands ducts resulting in painful oral ulcers. Therefore, understanding the pathogenesis of COVID-19 infection is vital for the development of robust infection control in dental offices and hospitals.

Based on the current findings, we propose that the incidence of oral manifestations of COVID-19 may have been underestimated in previous investigations [2] [3] [4] and that ACE2-expressing epithelial cells of the tongue and salivary glands may be vulnerable to SARS-CoV-2. Following oral keratinocytes/glandular tissue infection, there is an increased wall permeability to foreign pathogens and viral replication in the oral mucosal lining cells leading to ulcers and necrosis.

The limitations of this report are obvious. The cases reported were not sampled to show the presence of SARS-CoV2 in the oral lesions or saliva. In future studies, the characterization of the oral manifestations in COVID-19 infected individuals should include incisional biopsies followed by direct viral testing for SARS-CoV2. Because of the lack of oral tissue samples taken from our patients, we could not investigate the immunoexpression of ACE2 either. Consequently, we still have to consider that these lesions may be herpetic, immunologic, or erythema multiforme-like. Lastly, although the use of PBMT is well accepted in relieving pain secondary to oral ulcerative lesions of inflammatory nature, the fast onset and progression of the pandemic did not allow proper time for validating specific light protocols for COVID-19 patients. Therefore, the current approach should be considered empirical, although it was effective in controlling pain.

The duration of anosmia and ageusia could not be characterized among the patients of the current series because of their critical medical condition and intensive care hospitalization, which impaired their perception in terms of signs and symptoms. COVID-19-related olfactory and gustatory dysfunctions have been described as a possible surrogate marker of the SARS-CoV-2 infection, sometimes presenting as the only symptom of the disease. A meta-analysis has shown that olfactory dysfunction is observed in 52.73% of COVID-19 patients, and gustatory changes are noted in 43.93% of these individuals, and the use of validated instruments to asses these alterations seems to show even higher frequencies 15 . The awareness of these symptoms is important to encourage early diagnosis and treatment of the infection, but no importance beyond this is currently considered.

Considering that the length of symptoms burden is often short (nearly 9 days), and most of the patients will present complete resolution in 14 days 16 , no treatment has been used in the pandemic context. In fact, anosmia and dysgeusia treatments are often conducted by ENT or oral medicine specialists, which are not consulted due to the short duration of the symptoms and challenging medical scenario of the pandemic.

In conclusion, to our knowledge, these are the first reported cases of oral manifestations in COVID-19. The authors suggest a new possible etiopathogenic mechanism in the oral cavity between the ACE2 and SARS-CoV-2. This will require additional clinical and epidemiological data.

Awareness of such oral presentation is important because the oral lesions may precede the typical respiratory symptoms by several days, and oral lesion worsening may anticipate an aggravating clinical scenario. Additional studies need to investigate whether SARS-CoV-2 infection directly causes oral ulcerations or whether oral lesions are a coincidental event with COVID-19 progression.

The current case series validated 2-4 that dysgeusia and anosmia may develop early in patients infected by SARS-CoV-2 and should be considered a disease marker by dentists acting in the frontlines of the pandemic. Patients with complaints of lack of taste and smell may need to be evaluated preferably by telemedicine 17 or in person. The presence of dysgeusia or anosmia should be considered a potential indication of COVID-19. These individuals should be referred for diagnosis, be isolated and receive appropriate medical care. Dentists working in the hospital setting or in intensive care units should perform careful oral and oropharyngeal examination and document suspected cases of oral lesions in COVID-19 patient, especially in patient who complain of loss of taste and smell. 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Asymptomatic Infection

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Saliva: potential diagnostic value and transmission of 2019-nCoV

Consistent detection of 2019 novel coronavirus in saliva

The probability of detection of SARS-CoV-2 in saliva

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection

New Insights for the Pathogenesis of COVID-19-Related Dysgeusia

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Metaanalysis

Features of anosmia in COVID-19

Virtual assistance in oral medicine for prioritizing oral cancer diagnosis during the COVID-19 pandemic. Oral Surg Oral Med Oral Pathol Oral Radiol